Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Price Target at $14.50

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.50.

Several brokerages recently commented on NPCE. Wells Fargo & Company dropped their price objective on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their price target on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 4,031 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74. Following the completion of the transaction, the insider now owns 5,521,874 shares of the company’s stock, valued at $36,113,055.96. This represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 257,590 shares of company stock valued at $1,437,916 in the last 90 days. 22.20% of the stock is currently owned by company insiders.

Institutional Trading of NeuroPace

A number of institutional investors have recently made changes to their positions in NPCE. Barclays PLC grew its position in NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of NeuroPace by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after buying an additional 25,330 shares during the last quarter. State Street Corp grew its holdings in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after acquiring an additional 12,912 shares in the last quarter. Financial Advocates Investment Management increased its position in shares of NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after acquiring an additional 80,324 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Performance

Shares of NPCE stock opened at $11.53 on Friday. The stock has a market cap of $344.15 million, a PE ratio of -11.53 and a beta of 2.05. The stock has a 50-day moving average of $8.81 and a 200-day moving average of $7.72. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a one year low of $5.45 and a one year high of $18.15.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The firm had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. As a group, sell-side analysts expect that NeuroPace will post -1 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.